| abstract |
The invention discloses a temperature-sensitive gel for nasal influenza vaccine containing compound adjuvant, which is characterized by comprising influenza vaccine and vaccine adjuvant, and said vaccine adjuvant is a combination of TLR3 receptor agonist and nanoparticle adjuvant, The content of TLR3 receptor agonist in the gel solid content is 0.6-0.9%. The nasal influenza vaccine thermosensitive gel containing compound adjuvant provided by the present invention forms a compound adjuvant by selecting specific types and contents of adjuvant components, so that the prepared influenza vaccine thermosensitive gel can aggregate myocytes during the delivery process of the nasal mucosa. Effectively transcribed into cells to play a role, and can enhance the immune effect of influenza vaccine. |